1. Tumour escape from the immune response: the last hurdle for successful immunotherapy of cancer?

   • Graham Pawelec

   Article Pages: 343 - 345

2. Signaling defects in T lymphocytes of patients with malignancy

   • Theresa L. Whiteside

   REVIEW Pages: 346 - 352

3. Tumor-induced immune dysfunction

   • Rolf Kiessling
   • Ken Wasserman
   • Max Petersson

   REVIEW Pages: 353 - 362

4. Function and dysfunction of CD4⁺ T cells in the immune response to melanoma

   • Wolfgang H. Fischer
   • Per thor Straten
   • Jürgen C. Becker

   REVIEW Pages: 363 - 370

5. Targeting unique tumor antigens and modulating the cytokine environment may improve immunotherapy for tumors with immune escape mechanisms

   • Craig L. Slingluff

   REVIEW Pages: 371 - 373

6. Selective MHC expression in tumours modulates adaptive and innate antitumour responses

   • Robert C. Rees
   • Shahid Mian

   REVIEW Pages: 374 - 381

7. How tumors escape immune destruction and what we can do about it

   • Eli Gilboa

   REVIEW Pages: 382 - 385

8. In situ T cells in melanoma

   • Per thor Straten
   • Jürgen C. Becker
   • Jesper Zeuthen

   REVIEW Pages: 386 - 395

9. Vascular endothelial growth factor in malignant pleural effusion associated with lung cancer

   • Hiroaki Yanagawa
   • Eiji Takeuchi
   • Saburo Sone

   ORIGINAL ARTICLE Pages: 396 - 400

10. HER-2/neu peptide specificity in the recognition of HLA-A2 by natural killer cells

    • Larry D. Anderson Jr.
    • J. Michael Hudson
    • Constantin G. Ioannides

    ORIGINAL ARTICLE Pages: 401 - 410

11. Complement-mediated lysis of cultured osteosarcoma cell lines using chimeric mouse/human TP-1 IgG1 and IgG3 antibodies

    • Tove Olafsen
    • Charlotte K. Munthe Lund
    • Terje E. Michaelsen

    ORIGINAL ARTICLE Pages: 411 - 418

12. Effective cancer therapy with a single injection of interleukin-2 at the site of the tumour

    • Willem Den Otter
    • Jenny Cadée
    • Rachel Stewart

    SHORT COMMUNICATION Pages: 419 - 420